Adverse Event reporting information can be found in footer

Request a Meeting

NOQDIRNA

For adults with bothersome nocturia due to idiopathic nocturnal polyuria – whatever their age or gender

Nocturnal polyuria is often the underlying cause of nocturia.1 Noqdirna is proven to reduce bothersome night time voiding,2,3 and is the only licensed medication for the treatment of nocturnal polyuria for adults, including the over 65s.4,8

NOQDIRNA

(oral lyophilisate desmopressin [as acetate])

About Noqdirna

Noqdirna improves clinical outcomes and quality of life by reducing the number of nocturnal voids and nocturnal urine volume, improving patient response rates and lengthening the first uninterrupted sleep period.2,3

Learn More
nogdina stripe image
About Nocturia and Nocturnal Polyuria

Nocturia is defined as waking up to void one or more times during the night.5 Waking up two or more times is considered bothersome,6 affecting up to 60% of people over 70 years old and 17% of people between 20-40 years old.7

Learn More ➔
How to Identify At-Risk Patients

Are your patients suffering from increased night-time voiding? Find out how to identify patients at-risk of nocturnal polyuria and patients who could benefit from Noqdirna.

Learn More ➔
About Noqdirna

Find out more about Noqdirna, the only licensed medication for the treatment of idiopathic nocturnal polyuria for adults, including the over 65s.4, 8

Learn More ➔

Noqdirna – a low dose formulation of desmopressin that melts under the tongue without the need for water4,8

Due to its formulation, Noqdirna can be offered at gender-specific lower doses of desmopressin compared with existing formulations, without the same risk of hyponatraemia in the elderly (65 and over).2-4

Women: 25 microgram daily, one hour before bedtime, administered sublingually without water.8
Men: 50 microgram daily, one hour before bedtime, administered sublingually without water.4

Watch this short clip which shows how quickly the sublingual formulation dissolves versus the tablet formulation.

  1. Weiss JP et al. J Urol 2011;186:1358–1363.
  2. Sand PK et al. J Urol 2013;190:958–964.
  3. Weiss JP et al. J Urol 2013;190:965–972.
  4. Noqdirna Summary of Product Characteristics 50mcg. May 2016. Available at: http://www.medicines.org.uk/emc/medicine/32493. Date accessed: February 2023.
  5. van Kerrebroeck PV & Andersson KE. Neurourol Urodyn 2014;33 (Suppl 1):S2–S5.
  6. Everaert K et al. in Practical Functional Urology, Springer 2016. Edited by Heesakkers et al. pp 377–392.
  7. Bosch JL & Weiss JP. J Urol 2013;189:S86–S92.
  8. Noqdirna Summary of Product Characteristics 25mcg. May 2016. Available at: http://www.medicines.org.uk/emc/medicine/32493. Date accessed: February 2023.

Job Code: UK-NOQD-2000015 - Date of preparation: January 2023

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.